Exchange: AMEX Industry: Medical Instruments & Supplies
-0.46% $2.18
America/New_York / 10 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 179.04 mill |
EPS: | -0.270 |
P/E: | -8.07 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 82.13 mill |
Avg Daily Volume: | 0.333 mill |
RATING 2024-05-10 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.07 | sector: PE 12.30 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -8.07 | industry: PE 351.26 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.634 (-129.06%) $-2.81 |
Date: 2024-05-12 |
Expected Trading Range (DAY) |
---|
$ 2.00 - 2.36 ( +/- 8.07%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Peery Kimberly R. | Buy | 40 000 | Stock Options -Right to Buy |
2024-01-02 | Fischel Nathan | Buy | 64 935 | Common Stock |
2024-01-02 | Messey Robert J | Buy | 64 935 | Common Stock |
2024-01-02 | Curet Myriam | Buy | 64 935 | Common Stock |
2024-01-02 | Benfer David | Buy | 64 935 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 28 180 600 | Sell: 2 108 055 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.18 (-0.46% ) |
Volume | 0.217 mill |
Avg. Vol. | 0.333 mill |
% of Avg. Vol | 65.26 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.